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The Notch signaling pathway regulates many aspects of embryonic development, as well as differentiation
processes and tissue homeostasis in multiple adult organ systems. Disregulation of Notch signaling is asso-
ciated with several human disorders, including cancer. In the last decade, it became evident that Notch
signaling plays important roles within the hematopoietic and immune systems. Notch plays an essential
role in the development of embryonic hematopoietic stem cells and influences multiple lineage decisions
of developing lymphoid and myeloid cells. Moreover, recent evidence suggests that Notch is an important
modulator of T cell-mediated immune responses. In this review, we discuss Notch signaling in hematopoi-
esis, lymphocyte development, and function as well as in T cell acute lymphoblastic leukemia.Overview of Notch Signaling
The Notch signaling cascade is highly conserved and found in
organisms as diverse as worms and humans. In 1917, the genet-
icist Thomas Hunt Morgan and his colleagues described fruit
flies with notches at the margins of their wing blades (Morgan,
1917). It turned out that this notched wing phenotype is the result
of a partial loss of function of the Drosophila Notch gene, which
was cloned in the mid eighties (Kidd et al., 1986; Wharton et al.,
1985). Drosophila Notch encodes an unusual type I transmem-
brane receptor that is activated by two different membrane-
bound ligands called Delta and Serrate. Mammals posses four
Notch receptors (Notch1–4) that are bound by five ligands
(Delta-like1, 3, and 4 and Jagged 1 and 2) (Figure 1; Bray,
2006). The molecular and biochemical details of Notch signaling
have recently been covered by excellent reviews (Gordon et al.,
2008; Kopan and Ilagan, 2009). In brief, newly synthesized Notch
receptors are proteolytically cleaved in the Golgi (at site S1)
during their transport to the cell surface by a furin-like protease.
This cleavage generates a heterodimeric receptor consisting of
an extracellular subunit (NEC) that is noncovalently linked to
a second subunit containing the extracellular heterodimerization
domain and the transmembrane domain followed by the cyto-
plasmic region of the Notch receptor (N). The extracellular
part of the receptors contains 29–36 epidermal growth factor-
like repeats involved in ligand binding, followed by three
cysteine-rich LIN12 repeats that prevent ligand-independent
activation and a hydrophobic stretch of amino acids mediating
heterodimerization between NEC and N. The cytoplasmic tail
of the receptor harbors multiple conserved elements including
nuclear localization signals, as well as protein-protein interaction
and transactivation domains.
Notch signaling is initiated by ligand-receptor interaction
between neighboring cells, leading to two successive proteolytic
cleavages of the receptor. The first is mediated by metallopro-
teases of the ADAM family, which cleave the receptors 12–13
amino acids external to the transmembrane domain (at site
S2). The shedded extracellular domain is endocytosed by the
ligand-expressing cell, a process that is dependent on monoubi-
quitinylation of the cytoplasmic tail of the ligands by E3-ubiquitin14 Immunity 32, January 29, 2010 ª2010 Elsevier Inc.ligases of the mind bomb and neuralized family. Ligand binding
to NEC presumably induces a conformational change within the
Notch receptors to expose the S2 cleavage site for proteolysis.
After shedding of the extracellular domain, a second cleavage
within the transmembrane domain (at site S3) is mediated by
the g-secretase activity of a multiprotein complex. This liberates
the intracellular domain of Notch receptors (NICD), which subse-
quently traffics to the nucleus and heterodimerizes with the DNA
binding transcription factor CSL in order to form a short-lived
nuclear transcription complex. The transcription factor CSL is
also known as CBF-1 in humans, Suppressor of hairless in
Drosophila, Lag in Caenorhabditis elegans, and RBP-J in the
mouse. Once bound to CSL, NICD recruits other coactivators
including mastermind proteins (MAML1-3), which in turn recruit
the MED8-mediator transcription activation complex in order
to induce transcriptional expression of downstream target genes
(Figure 2). Members of the Hairy enhancer of split (Hes) or Hairy
related (Hey or Hrt) genes have been identified as Notch target
genes in many tissues, while other targets are more tissue
restricted. Recent studies via genome-wide expression and
chromatin immunoprecipitation (ChIP) arrays point to the exis-
tence of a large number of genes that can be directly regulated
by Notch (Palomero et al., 2006; Weng et al., 2006). The chal-
lenge will now be to distinguish the drivers from the passengers
among the large number of target genes. Moreover, there is
emerging data suggesting that Notch can crosstalk to or coop-
erate with other signaling pathways (including NF-kB, hypoxia,
or TGF-b) and thereby broaden the spectrum of target genes
that are influenced by Notch signaling (Poellinger and Lendahl,
2008; Samon et al., 2008).
Notch signaling is regulated at multiple levels. For example,
cell type-specific and spatial expression of ligands and Notch
receptors can restrict signaling to a certain cell population or
context. The ability of Jagged ligands to trigger Notch
receptor-mediated signaling is dependent on the glycosylation
status of the extracellular domain of Notch. Fringe proteins are
glycosyl transferases that add N-Acetylglucosamine to O-fucose
residues present within certain epidermal growth factor-like
repeats of the receptors (Haines and Irvine, 2003). Notch
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Figure 1. Notch Ligands and Receptors
To date, five conventional Notch ligands are known: Jagged1 (J1), Jagged2
(J2), Delta-like1 (Dll1), Delta-like3 (Dll3), and Delta-like4 (Dll4). A common
structural feature of all ligands is an amino-terminal domain called DSL (Delta,
Serrate, and Lag-2) involved in receptor binding followed by EGF-like repeats.
A cysteine-rich domain (CR) is located downstream of the EGF-like repeats of
J1 and J2 close to the plasma membrane (PM). Vertebrates have four Notch
receptors (Notch1–Notch4; N1–N4). The extracellular domain of the receptors
contains EGF-like repeats (36 in N1 and N2, 34 in N3, and 29 in N4) followed by
three cysteine-rich LIN domains that prevent ligand-independent activation
and the heterodimerization domain (HD). The cytoplasmic domain contains
a RAM domain followed by six ankyrin repeats (ANK) that bind to the CSL tran-
scription factor, two nuclear localization signals (NLS), a transactivation
domain (TAD; present in N1 and N2), and a PEST sequence involved in regu-
lating protein stability.
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signal via Delta ligands, while Jagged-mediated Notch signaling
is inhibited. Another level of regulation is to ensure that a Notch
signal is short lived. Notch receptors carry a PEST domain at the
very C terminus that is responsible for rapid turnover of the acti-
vated NICD via E3-ubiquitin ligase (including Fbw7)-mediated
proteosomal degradation (Figure 2; O’Neil et al., 2007; Thomp-
son et al., 2007).
Notch in Hematopoietic Stem Cell Development
and Homeostasis
The blood system originates from different sites during embry-
onic development and is generally closely associated with vas-culogenesis. The most primitive hematopoietic cells are found
within the extraembryonic yolk sac before hematopoiesis shifts
to intraembryonic sites including the para-aortic splanchno-
pleiura and aorta-gonad mesonephros (P-sP and AGM). Later
hematopoiesis occurs in the fetal liver before it is finally estab-
lished in the bone marrow (Godin and Cumano, 2002). The first
hematopoietic stem cells capable of long-term repopulation of
all blood lineages upon transplantation are found within the
AGM region. These cells are generated from a bipotent heman-
gioblast by budding off from the dorsal aorta of midgestation
embryos (de Bruijn et al., 2002). Germline mutant embryos defi-
cient for Notch1 or RBP-J have been shown not to generate in-
traembryonic HSCs, whereas yolk sac hematopoiesis of these
mutant mice was unperturbed (Kumano et al., 2003; Robert-
Moreno et al., 2005). These studies led to the suggestion that
Notch signaling is important for definitive but not primitive hema-
topoiesis. However, Notch signaling is also important for arterial
cell fate specification in developing blood vessels. Hence, these
mutant embryos displayed severe vasculogenic defects charac-
terized by the loss of arterial cell fate (Krebs et al., 2004). There-
fore, it was not clear whether the inability to generate intraem-
bryonic HSC is a cell-autonomous defect of hemangioblasts
or simply a secondary effect resulting from the absence of
arteries. This uncertainty was recently resolved by studies
analyzing germline mutant mice for the Jagged ligand family.
Jagged1 but not Jagged2 null embryos failed to generate
hematopoietic cells in the AGM, without losing the arterial cell
fate (Robert-Moreno et al., 2008). Moreover, the same study
linked Jagged1-mediated Notch signaling to GATA2 and
Runx1 expression, two important transcription factors for hema-
topoiesis. These observations were important because they
were the first studies showing that Notch signaling is directly
associated with the generation of hematopoietic cells indepen-
dently of its role in arterial development. Thus, Notch signaling
is indeed essential for definitive hematopoiesis in the developing
embryo.
Whether Notch signaling plays a similar role during the gener-
ation or maintenance of HSC in the adult bone marrow compart-
ment was debated for several years. Jagged1 was suggested to
be part of the HSC stem cell niche, because osteoblast-specific
expression of the parathyroid hormone-related protein receptor
(PTHRP) resulted in increased numbers of Jagged1-expressing
osteoblasts, which correlated with increased numbers of
HSCs. This result led to the suggestion that Jagged1-mediated
Notch signaling might regulate HSC homeostasis (Calvi et al.,
2003). Moreover, multiple gain-of-function studies support
a role for Notch in HSC maintenance. Overexpression of
N1-ICD or its downstream target gene Hes1 in bone marrow pro-
genitors resulted in increased HSC numbers and/or enhanced
self-renewal (Kunisato et al., 2003; Stier et al., 2002). Coculture
experiments of murine hematopoietic progenitor cells with im-
mobilized Notch ligands promoted early T cell differentiation
and generation of multilog increases in the number of hemato-
poietic progenitor cells with short-term lymphoid and myeloid re-
populating activity (Varnum-Finney et al., 2003). The dose of
Notch signaling determines the in vitro process of hematopoietic
progenitor cell expansion versus B and/or T cell differentiation.
Coculture of hematopoietic progenitor cells in the presence of
high densities of Notch ligands increases the propensity to driveImmunity 32, January 29, 2010 ª2010 Elsevier Inc. 15
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Figure 2. Notch Signaling
Notch proteins are synthesized as single
precursor proteins, which are cleaved in the Golgi
by a Furin-like convertase at site S1. Cleavage at
S1 generates two subunits held together non-
covalently by the N- and C-terminal subunits of
the heterodimerization domains (HD). EGF-like
repeats are glycosylated by Fringe proteins in
the Golgi before receptors are transported to the
cell surface. Notch signaling is initiated by ligand
receptor interaction, which induces a second
cleavage at site S2 (close to the transmembrane
domain) mediated by ADAM-type metallopro-
teases followed by a third cleavage at S3 within
the transmembrane domain mediated by the
g-secretase activity of a multiprotein complex
containing presenilins. This last proteolytic
cleavage liberates the cytoplasmic domain of
Notch receptors (NICD), which translocate to the
nucleus and bind to the transcription factor CSL
(CBF1, Suppressor of hairless, and Lag-1), con-
verting it from a transcriptional repressor into
a transcriptional activator by recruiting coactiva-
tors including mastermind-like proteins (MAML).
NICD is polyubiquitinated by E3 ubiquitin ligases
(including Fbw7), which marks NICD for proteoso-
mal degradation.
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particular, the finding that human umbilical cord blood cells
(UCB) could also be expanded ex vivo when cocultured with
Delta-like1-IgG fusion proteins and that these cells showed
a marked increase (approximately 15-fold) in repopulating cell
frequency in xenotransplantation assays (Delaney et al., 2005)
may be exploited for clinical purposes (Bernstein et al., 2008).
Although it is very encouraging that Notch ligands are currently
used to expand murine and human hematopoietic progenitors,
there is limited evidence that Notch can be used to expand
long-term HSCs. Thus, the question remains whether this is
a physiological role of Notch signaling. This has been addressed
by analyzing several conditional gene-targeted mice for different
components of the Notch pathway. Mice lacking Notch1 or
Jagged1 or both did not reveal any defects in HSC maintenance
or in the capacity to repopulate the hematopoietic compartment
after transplantation (Mancini et al., 2005; Radtke et al., 1999).
These results do not exclude the possibility that other Notch
receptors or ligands might functionally compensate for the loss
of Notch1 and/or Jagged1. Two complementary approaches
were recently used to block canonical Notch signaling. The first
used a dominant-negative form of the Mastermind-like protein,
which inhibits the formation of a functional Notch transactivation
complex in HSCs and bone marrow (BM) progenitors, whereas
the second inactivated the Rbp-j gene within HSCs. These
experimental approaches block Notch signaling independently
of Notch receptor or ligand usage. Notch signaling-deprived
progenitors did not reveal any HSC defects; they showed normal
long-term reconstitution even in secondary competitive trans-
plantation assays (Maillard et al., 2008). Taken together, these
experiments show that canonical Notch signaling is dispensable
for HSC homeostasis in the bone marrow. Moreover, the identi-
fication of the proto-oncogene LRF (Leukemia/lymphoma
Related Factor, encoded by the Zbtb7a gene and also known
as Pokemon) as a negative regulator of Notch signaling in BM
progenitors indicates that Notch signaling must be repressed16 Immunity 32, January 29, 2010 ª2010 Elsevier Inc.or under very stringent control in HSCs in order to prevent
ectopic T cell differentiation in the BM (Maeda et al., 2007).
How LRF represses Notch signaling in HSC or progenitor cells
is currently unknown.
Notch in T Cell Development
The essential role of Notch signaling during thymic T cell lineage
commitment and maturation is the best-studied function of Notch
in hematopoiesis. Via the blood stream, BM progenitors
constantly seed the thymus, where they adopt a T cell fate and
further differentiate into mature ab and gd T cells before
emigrating to the periphery. Multiple genetic loss- and gain-of-
function studies highlight the importance of Notch1 for T cell
lineage commitment. Inducible inactivation of Notch1 or Rbp-j
results in a block in T cell development accompanied by the accu-
mulation of ectopic B cells in the thymus (Han et al., 2002; Radtke
et al., 1999). These results were initially interpreted to mean that
canonical Notch1 signaling instructs a bipotent early thymic
progenitor to adopt a T cell as opposed to a B cell fate because
no other myeloid or lymphoid lineages were affected. Neverthe-
less, recent loss of Notch1 function combined with lineage
tracing experiments reveal that the inhibitory functions of Notch1
are broader. Notch1 inhibits multiple cell fate potentials of
thymus-seeding cells including myeloid and B cells, as well as
conventional and plasmacytoid dendritic cell potential (both in
a cell-intrinsic and -extrinsic manner) and thereby ensures effi-
cient T cell lineage commitment (Bell and Bhandoola, 2008;
Feyerabend et al., 2009; Wada et al., 2008). Similarly, interference
with Notch signaling by transgenic expression of Notch modula-
tors (including Fringe, Deltex1, or Nrarp) or dominant-negative
forms of the transcriptional coactivator MAML-1 also blocks
T cell development concomitant with B lymphopoiesis in the
thymus (Izon et al., 2002; Koch et al., 2001; Maillard et al.,
2004; Yun and Bevan, 2003). Reciprocal gain-of-function studies
involving overexpressing N1-ICD in BM progenitors result in
ectopic T cell development at the expense of B cell development
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strate that Notch1 is the key receptor expressed on thymus-
seeding cells responsible for T cell lineage commitment.
The question of the ligand(s) required for this process was
recently addressed. Historically, Dll1 and somewhat later Dll4
have been favored as potential Notch1 ligands for T cell fate
specification based on their capacity to support complete devel-
opment of mature T cells from BM precursors in vitro (Hozumi
et al., 2004; Jaleco et al., 2001; Schmitt and Zu´n˜iga-Pflu¨cker,
2002). Nevertheless, inactivation of Dll4 but not Dll1 in thymic
epithelial cells (TECs) resulted in a complete block in T cell devel-
opment accompanied by ectopic B cell development within the
thymus, which phenocopies mice with loss of Notch1 function
in BM progenitors (Hozumi et al., 2008; Koch et al., 2008). These
results demonstrate an essential interaction between Dll4-ex-
pressing TECs and thymus-seeding Notch1-expressing hema-
topoietic progenitors for T lineage commitment. Previous studies
of the thymic epithelium of gene-targeted mice in which T cell
development is arrested at early developmental stages showed
that the thymocyte progenitors also influence TEC maturation
and function. Thus, lymphostromal interactions between devel-
oping thymocytes and TECs are bidirectional, a concept known
as ‘‘thymus crosstalk’’ (van Ewijk et al., 1994). In this context,
a recent report showed that maturation of thymocytes to the
CD4+CD8+ stage induced downregulation of Dll4 on cortical
TECs suggesting a negative-feedback loop between developing
thymocytes and cortical TECs (Fiorini et al., 2008). This coincides
with the maturation and the ability of medullary TECs to mediate
positive and negative selection, a trait that is acquired in a thymo-
cyte-dependent manner (Alves et al., 2009). How and whether
downregulation of Dll4 on cortical TECs is essential to allow posi-
tive and/or negative selection remains an open question.
Once the T cell lineage has been specified, developing thymo-
cytes must choose between the ab and gd T cell lineage. gd T cell
development is mostly driven by the successful rearrangement
of T cell receptor g (TCR-g) and TCR-d genes and appears to
be Notch independent (Ciofani et al., 2006; Wolfer et al., 2002).
Interestingly, the helix-loop-helix protein Id3 can induce promo-
tion of the gd T cell fate as well as rendering gd T cell maturation
independent of Notch signaling (Lauritsen et al., 2009). In con-
trast, ab T cell development requires continuous Notch signaling
up to the DN3 stage, where cells have to pass a critical check-
point known as b-selection (Wolfer et al., 2002).
Although it is well established that signaling via the pre-TCR
(consisting of productively rearranged TCR-b chain associated
with CD3 components and an invariant pTa chain) is essential
for b-selection and further thymocyte development, in vitro
experiments suggest that successful transition through this
checkpoint requires cooperative signaling of both Notch and
pre-TCR (Ciofani et al., 2006). This leads to the question of how
this functional cooperativity is established at the molecular level
and whether Notch and pre-TCR signaling influence each other.
Loss-of-function experiments for both Notch signaling and
components of the pre-TCR highlight the essential role of each
individual signaling pathway during thymocyte development.
For example, the consequences of a loss of Notch signaling
in vivo (via a dominant-negative MAML-1) in immature thymo-
cytes prior to the b-selection checkpoint cannot be overcome
by TCR-b or TCR-ab transgenes, suggesting that the require-ment for early Notch signaling is absolute and independent of
the pre-TCR (Maillard et al., 2006). Similarly, RAG2-deficient
thymocytes (which lack a pre-TCR because of the inability to re-
arrange a functional TCR-b chain) cannot progress to the DP
stage even if they receive a Notch signal (Allman et al., 2001).
Nevertheless, successful transition through b-selection requires
the cooperative action of both Notch and the pre-TCR. As thymo-
cytes pass through b-selection, Notch assures survival by regu-
lating glucose metabolism (Ciofani and Zu´n˜iga-Pflu¨cker, 2005).
Moreover, transcriptional reporter assays combined with ChIP
experiments suggest a direct crosstalk between Notch and
pre-TCR because Notch1 and/or Notch3 (which is a Notch1
target gene) can directly activate the transcription of the pTa
gene (Bellavia et al., 2007; Reizis and Leder, 2002). Additional,
indirect regulation of pTa gene expression by Notch involves
Notch3 and Ikaros. Ikaros functions as a transcriptional repressor
and recognizes the same DNA binding sites as Rbp-j. Thus,
Ikaros and Rbp-j can potentially compete for the same DNA
binding site, a process that has been shown to be important
during T cell leukemogenesis (Beverly and Capobianco, 2003;
Dumortier et al., 2006). Notch3 activation results in the expres-
sion of HuD, a RNA binding protein that can trigger the generation
of non-DNA binding Ikaros isoforms through alternative splicing.
These isoforms competitively block the activity of full-length
Ikaros and thereby facilitate the upregulation of pTa directly
through Notch-Rbp-j-mediated transcriptional complexes (Bel-
lavia et al., 2007). Thus, Notch1 signaling directly and indirectly
participates in the generation of the pre-TCR.
This leads to the question of how Notch1 itself is regulated
during thymocyte development. Notch1 (in an autoregulatory
loop) together with the transcription factor E2A directly contrib-
utes to the progressive increase of Notch1 expression at the
earliest stages of thymocyte development, prior to the b-selec-
tion stage. Thymocytes that successfully pass b-selection imme-
diately downregulate the expression of Notch1 (Taghon et al.,
2006; Yashiro-Ohtani et al., 2009). This process is driven via
the pre-TCR-mediated induction of the HLH transcription factor
Id3. Id3 is an inhibitor of E-proteins and as such inhibits E2A-
dependent activation of Notch1 transcription, leading to
a decrease in Notch1 mRNA. Taken together, Notch1-mediated
signaling is necessary for assembling a functional pre-TCR and
as soon as thymocytes pass b-selection, the pre-TCR ensures
the transcriptional repression of Notch1, a mechanism that is
presumably essential to avoid the oncogenic properties of Notch
signaling and its targets (see below) (Weng et al., 2006). Interest-
ingly, the abrupt downregulation of Notch1 transcription after b-
selection is not reflected at the protein level. Surface expression
of Notch1 receptor remains at equally high amounts from DN3
stage until the ISP stage and decreases only subsequently in
DP thymocytes (Fiorini et al., 2009). These results suggest that
the decrease in Notch1 transcription and Notch1 target gene
expression after b-selection may occur independently of the
regulation of Notch1 surface expression. Thus, it is conceivable
that downregulation of Notch1 target genes is not simply the
result of absence of Notch signaling resulting from lack of
Notch1 surface expression, but may also implicate additional
repressive mechanisms. Interestingly, Ikaros is implicated in
the negative regulation of the Notch target gene Hes1 in thymo-
cytes that successfully passed b-selection. DN4 thymocytesImmunity 32, January 29, 2010 ª2010 Elsevier Inc. 17
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Notch signaling. This event correlates with epigenetic silencing
of the Hes1 locus, suggesting that Ikaros might help to shut
down Notch target genes once thymocytes passed b-selection
(Kleinmann et al., 2008).
Notch in Marginal Zone B Cell Development
A second well-characterized role for Notch signaling in the
lymphoid system involves the specification of marginal zone
(MZ) versus follicular B cell fate in the spleen. Mature splenic
B cells are comprised of two principal subsets, follicular B cells
and MZ B cells (Pillai and Cariappa, 2009). Follicular B cells, which
are the most abundant subset, are recirculating cells that home to
B cell follicles and participate in T cell-dependent immune
responses to protein antigens. In contrast, MZB cells are not re-
circulating and localize in the outer region of the splenic white
pulp between the marginal sinus and the red pulp. MZB cells
provide an important line of defense against blood-borne patho-
gens by mounting T cell-independent antibody responses. In
addition, MZB cells express high amounts of CD1d, which allows
them to capture lipid antigens from the circulation and present
them to CD1d-restricted Va14 invariant natural killer T cells. In
some respects, MZB cells can thus be considered to be an
‘‘innate-like’’ population because they exhibit a constitutively
activated phenotype similar to NK cells, NKT cells, and gd T cells.
Both MZB cells and follicular B cells in the spleen are derived
from B lineage progenitors in the BM. During development,
immature B cells that productively rearrange heavy- and light-
chain immunoglobulin genes express a B cell receptor (BCR)
at the cell surface. Similar to T cells, immature B cells that
express strongly self-reactive BCR undergo clonal deletion or
receptor editing. Further B cell maturation proceeds through
transient transitional stages (T1 and T2), ultimately leading to
the differentiation of mature follicular or MZB cells in the spleen.
The specification of splenic follicular versus MZB cell fate from
immature T2 B cells is determined by several factors and has
been reviewed in detail recently (Pillai and Cariappa, 2009). In
this section, we will concentrate on Notch signaling, which has
a critical and nonredundant role in specifying MZB cell fate.
It is now widely accepted that MZB cell fate specification in the
spleen depends upon nonredundant interaction between
Notch2 and Dll1. Thus mice conditionally deficient in either
Notch2 or Dll1 have greatly reduced numbers of MZB cells (Ho-
zumi et al., 2004; Saito et al., 2003). Further evidence supporting
a requirement for Notch signaling in MZB cell development
comes from the analysis of mice deficient in other components
of the Notch signaling pathway such as Rbp-j (Tanigaki et al.,
2002) or MAML1 (Oyama et al., 2007; Wu et al., 2007), which
also fail to generate MZB cells. In reciprocal experiments, dele-
tion of MINT (a negative regulator of Notch signaling) led to an
increase in splenic MZB cells (Kuroda et al., 2003). Collectively
these loss-of-function experiments provide compelling evidence
that the strength of signaling via Notch2:Dll1 interactions
controls the rate of development of MZB cells.
Although it has been known for some time that Dll1 is the rele-
vant ligand of Notch2 in MZB cell development, the identity of
Dll1-expressing cells in the spleen remained elusive. Nonhema-
topoietic cells (Hozumi et al., 2004), and in particular endothelial
cells located in the red pulp and MZ of the spleen (Tan et al.,18 Immunity 32, January 29, 2010 ª2010 Elsevier Inc.2009), selectively express Dll1. It seems likely that endocytosis
of Dll1 by these ligand-expressing endothelial cells may be
required for efficient signaling via Notch2 on MZB cells or their
precursors, because deletion of Mindbomb 1 (Mib1), an E3
ligase known to regulate Dll1 endocytosis, phenocopies condi-
tional Notch2 and Dll1 mutant mice (Song et al., 2008).
Another modulator of Notch signaling that plays an important
role in MZB cell development is the Fringe family of glycosyl-
transferases. As discussed earlier, Fringe can enhance interac-
tions of Notch receptors and Dll ligands by adding N-acetyl
glucosamine to O-linked fucose residues on Notch. Two
members of the Fringe family (Lunatic fringe and Manic fringe)
function cooperatively to strengthen the presumably weak inter-
action between Notch2 on MZB cells (or their precursors) and
Dll1-expressing endothelial cells in splenic niches, thereby
promoting development of the MZB cell lineage (Tan et al.,
2009). According to this scenario, MZB cell homeostasis
depends upon Fringe-regulated competition between Notch2-
expressing precursor cells for access to Dll1 ligands.
Notch in Other Hematopoietic Lineages
Although much attention has been focused on the controversial
role of Notch signaling in HSC homeostasis and differentiation,
Notch may also play a role in other cell fate decisions within
the hematopoietic system. Thus megakaryocyte development
is enhanced in vitro when BM precursors are cocultured with
Dll1-expressing OP9 stromal cells (Mercher et al., 2008). In recip-
rocal experiments, inhibition of canonical Notch signaling in vivo
by a dominant-negative MAML1 decreased megakaryocyte
numbers, but (somewhat surprisingly) did not affect platelet
counts, even after challenge with 5-Fluorouracil (5-FU) (Mercher
et al., 2008). Further studies will be needed to identify the phys-
iologically relevant Notch receptors and ligands implicated in the
development of the megakaryocyte lineage in vivo.
Dendritic cells (DCs) appear to be another hematopoietic
lineage that is influenced by Notch signaling during develop-
ment. Several in vitro systems have demonstrated that Dll1-
mediated Notch signaling promotes the development of either
plasmacytoid or conventional DCs at the expense of other line-
ages such as T cells or macrophages (Ohishi et al., 2001; Olivier
et al., 2006). Moreover, differentiation of ES cells or BM progen-
itors into DCs in vitro was shown to depend upon Notch signaling
via downstream activation of the Wnt pathway (Zhou et al.,
2009). More compellingly, loss of function of canonical Notch
signaling via Rbp-j inactivation specifically in the DC lineage
led to a selective impairment of the splenic CD8 DC subset
(Caton et al., 2007). Intriguingly, CD8 DCs in the spleen were
found adjacent to unidentified Dll1-expressing cells in the mar-
ginal zone, raising the possibility that CD8 DCs may compete
with MZB cells for Notch signals during development (see
previous section). In a genetic fate mapping model, inactivation
of Notch1 in early intrathymic precursors revealed their potential
to develop into DCs in the thymus (Feyerabend et al., 2009).
Taken together, these experiments indicate that at least some
aspects of DC development may depend upon Notch signaling.
Notch in Peripheral T Cell Differentiation and Function
Once T cells leave the thymus, they migrate to the periphery,
where they orchestrate immunity against different pathogens.
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Figure 3. Consensus on the Role of Notch in Peripheral T Cell Differentiation
After encounter with pathogens, Notch ligands are upregulated on antigen-presenting cells (APCs). Activation of naive CD8+ T cells requires binding of Dll1 on
APCs to N1 or N2 receptors. After receptor:ligand interaction N1-ICD is liberated and moves to the nucleus where it binds to Eomes,Prf1, andGzmb promoters to
activate functional CD8+ T cells producing IFN-g. Alternatively, N2-ICD interacts with CREB1 to bind the Gzmb promoter. Naive CD4+ T cells are generally
induced to become Th1 or Th2 cells. Th1 cell-inducing microbes upregulate Dll ligands on APCs. Then, N1-ICD can directly promote Th1 cell differentiation
by binding to CSL on the Tbx21 promoter or by activating the NF-kB pathway, eventually leading to IFN-g production. After exposure to Th2 cell stimuli,
APCs upregulate ligands of the Jagged family. N1-ICD and N2-ICD induce Th2 cell differentiation by forming complexes with CSL, either on the upstream
promoter of Gata3 or on a 30 enhancer of the Il4 gene, ultimately leading to the production of IL-4, IL-5, and IL-13.
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vated and exert their function. For example, cytotoxic CD8+
T cells are recruited against viruses and kill infected cells by
the production of interferon-g (IFN-g) and cytotoxic molecules
including granzyme B and perforin. Pathogens such as bacteria,
helminths, fungi, and also viruses are recognized by antigen-pre-
senting cells (APCs), which then activate CD4+ T helper (Th) cells.
These cells drive adaptive immunity and induce specific
responses against these microbes. Although first classified as
either Th1 or Th2 cells according to their cytokine profiles, it
appears that many more discrete Th cell subsets exist, exempli-
fied by the newly characterized Th17 cells. Th1 cells produce
IFN-g and are involved in the fight against intracellular patho-
gens, whereas Th2 cells secrete interleukin-4 (IL-4), IL-5, and
IL-13 and provide immunity to helminths. Moreover, some extra-
cellular bacteria and fungi are cleared by the presence of Th17
cells that produce IL-17 and recruit neutrophils to the site of
infection (Weaver et al., 2007). Once an immune response has
been initiated, it has to be dampened and/or switched off again
in order to avoid exaggerated immune responses that could
cause autoimmunity or allergies. Notch signaling has been asso-
ciated with all of the above-mentioned functions. The multitude
of different disease models used has contributed to a complex
picture of possible Notch functions in peripheral immune
responses. A potential role for Notch signaling in peripheral
T cells linked Notch receptor expression to T cell activation,
proliferation, and cytokine production. TCR activation of periph-
eral T cells in vitro led to upregulated expression of Notch1,
which correlated with increased proliferation. g-secretase inhib-itor (GSI)-mediated inhibition of Notch signaling in peripheral
CD4+ and CD8+ T cells resulted in decreased T cell proliferation
and reduced IFN-g production (Palaga et al., 2003). A second
study showed that forced NICD expression can induce a positive
feedback loop by increasing IL-2 production and the expression
of the IL-2 receptor a-subunit on T cells in vitro (Adler et al.,
2003). Notch signaling is also associated with the differentiation
of naive CD8+ T cells to cytotoxic T lymphocytes (CTLs),
a process that is in part mediated by the upregulation of the tran-
scriptional regulator eomesodermin (Eomes), which regulates
the expression of perforin and granzyme B (Cho et al., 2009).
Interestingly, this study showed that Notch1 regulates the
expression of all three genes that encode Eomes, perforin, and
granzyme B through direct binding to the corresponding
promoter. Moreover, CTLs in mice expressing a Notch1 anti-
sense transgene showed decreased expression of Eomes, per-
forin, and granzyme B, and GSI-mediated inhibition of Notch
signaling attenuated CTL function (Cho et al., 2009). Similarly,
Notch2 was also reported to regulate granzyme B expression.
N2-ICD was shown to interact with the transcription factor
CREB1 and together to bind to the granzyme B promoter.
Notch2-deficient CD8+ T cells produced lower amounts of gran-
zyme B after stimulation with Dll1-expressing DCs in vitro
compared to control animals (Figure 3; Maekawa et al., 2008).
Taken together, these experiments suggest that Notch
signaling can participate in regulating genes necessary for CTL
differentiation and function; however, whether Notch signaling
is required in vivo for mounting an efficient CTL response against
a viral infection has not been investigated.Immunity 32, January 29, 2010 ª2010 Elsevier Inc. 19
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Another function that was assigned to Notch is the regulation of
Th cell differentiation. The differentiation of naive CD4+ T cells to
different Th cell subsets is regulated, first by TCR and costimu-
latory signals and then by cytokines present in the environment.
In this context, IL-12 produced by APCs drives naive CD4+
T cells to differentiate into Th1 cells, whereas IL-4 present in
the milieu allows Th2 cell polarization. Although certain aspects
of how Notch regulates Th cell differentiation are controversial,
the consensus is that Notch is essential for Th2 cell differentia-
tion but can also influence a Th1 cell response.
The evidence that Notch signaling is important for Th1 cell
induction is mostly derived from experiments implicating Notch
ligands or from studies with pharmacological Notch inhibitors.
APCs encountering pathogens that promote their ability to
mount a Th1 cell response show an upregulation of the Notch
ligands Dll1 and/or Dll4 (Amsen et al., 2004; Skokos and Nus-
senzweig, 2007; Sun et al., 2008). Moreover, ectopic expression
of Dll ligands on DCs promoted Th1 and inhibited Th2 cell differ-
entiation (Amsen et al., 2004; Krawczyk et al., 2008; Maekawa
et al., 2003). Th1 cell induction by forced Dll expression required
the presence of the Th1 cell transcription factor T-bet, which was
dispensable for Dll-mediated inhibition of Th2 cells (Krawczyk
et al., 2008). In addition, Dll ligands were suggested to inhibit
Th2 cell differentiation by interfering with IL-4 receptor signaling
(Krawczyk et al., 2008). Skokos and colleagues investigated the
dependence of Dll4-mediated signaling within different splenic
DC subsets for their capacity to induce a Th1 cell response after
LPS exposure. CD8 DCs upregulated Dll4 in response to LPS
but did not express IL-12. In contrast, CD8+ DCs expressed
IL-12 but not Dll4. Inhibition of Notch signaling (with a Dll4-Fc
fusion protein) of CD8+ DCs expectedly did not affect Th1 cyto-
kine production. In contrast, inhibition of CD8 DCs led to
a pronounced reduction of IFN-g production. Taken together,
these results suggest that Dll4-mediated Notch signaling might
be involved in the generation of IL-12-independent Th1 cell
responses (Skokos and Nussenzweig, 2007).
The identity of the Notch receptors that mediate Dll-induced
Th1 cell differentiation is currently unclear. Two reports showed
that retroviral expression of either N1-ICD or N3-ICD led to the
generation of Th1 cells with a mechanism that was independent
of IL-12 (Maekawa et al., 2003; Minter et al., 2005). However,
genetic inactivation of Notch1 did not affect Th1 cell differenti-
ation (Tacchini-Cottier et al., 2004), suggesting that the devel-
opment of Th1 cells may require Notch3 rather than Notch1-
mediated signaling. Consistent with this possibility is the finding
that the Th1 cell response in an experimental autoimmune
encephalomyelitis (EAE) model (murine model of multiple scle-
rosis) was inhibited after Notch3, but not Notch1, blockade.
This correlated with the downregulation of protein kinase C
theta (PKCq), which plays an important role in the regulation
of Th1 cell differentiation (Jurynczyk et al., 2008). Finally, GSI-
mediated inhibition of Notch signaling suppressed the Th1
cell immune response in vitro and in vivo. Moreover, the
same study showed that exogenous N1-ICD and Rbp-j were
able to form transcriptional complexes on the Tbx21 promoter
(of the T-bet gene), indirectly suggesting that Notch might tran-
scriptionally regulate T-bet expression (Figure 3; Minter et al.,
2005).20 Immunity 32, January 29, 2010 ª2010 Elsevier Inc.Notch may induce the promotion of Th1 cells by interacting
with the NF-kB pathway. Complexes of Notch1 and NF-kB1
(p50) or N1-ICD and RelA (p65) could be immunoprecipitated
on the Ifng promoter, in regions lacking Rbp-j binding sites
(Shin et al., 2006). This raises the possibility that N1-ICD can
contribute to Th1 cell differentiation in a Rbp-j-independent
manner (Figure 3).
Although a role for Notch in the promotion of the Th1 cell
lineage is well documented, genetic evidence for the absolute
requirement of Notch signaling is lacking. Indeed, inactivation
of Rbp-j or both Notch1 and Notch2 (N1N2) or T cell-specific
expression of dominant-negative MAML1 had no effects on
Th1 cell differentiation (Amsen et al., 2004, 2007; Tu et al.,
2005), suggesting that Notch signaling is not essential for Th1
cell differentiation.
Notch in Th2 Cells
The cell fate decision between Th1 and Th2 cells may depend on
the ligand used to activate Notch signaling. Expression of Jagged
ligands, but not Dll, on the surface of APCs was shown to induce
Th2 cell differentiation in vitro (Amsen et al., 2004). Jagged2 is
induced on DCs after stimulation with multiple Th2 cell-inducing
products such as Schistosoma egg antigen (SEA), dust-mite
extracts, or Prostaglandin E2 (Amsen et al., 2004; Krawczyk
et al., 2008; Worsley et al., 2008). However, although capable
of driving Th2 cell differentiation in vitro, Jagged2 seems to be
dispensable in vivo for Th2 cells (Krawczyk et al., 2008; Worsley
et al., 2008). In contrast, expression of Jagged1 on DCs might
be involved in the initial phase of Th cell differentiation by inducing
IL-4 production in a model of airway hyperresponsiveness (Oka-
moto et al., 2009). Taken together, these data implicate Jagged
ligands in the development of Th2 cell immune responses. How
Dll- and Jagged-mediated Notch signaling differ on the molecular
level to drive Th1 or Th2 cell differentiation is currently unknown.
Genetic loss-of-function experiments showed that Notch
signaling is dispensable for Th1 cell differentiation, and addition-
ally they were instrumental to demonstrate that Notch is essen-
tial for the development of Th2 cell immune responses in physi-
ological settings such as parasite infection (Amsen et al., 2004,
2007). For example, mice in which Notch signaling was inhibited
in T cells through dominant-negative MAML could not mount
a protective Th2 cell response against the intestinal parasite Tri-
churis muris in vivo (Tu et al., 2005). Moreover, mice deficient for
Rbp-j or N1N2 in T cells and immunized with Th2 cell antigens or
alum adjuvants were incapable of mounting a Th2 cell immune
response in vivo. However, addition of exogenous IL-4 in vitro
restored the ability of these T cells to generate a Th2 cell cytokine
profile (Amsen et al., 2004, 2007). In another set of experiments,
GSI treatment after ovalbumin immunization in an asthma model
led to a decrease in Th2 cell cytokine production and inhibition of
NF-kB signaling (Kang et al., 2009).
Although Th1 cell immune responses can be induced in an
Rbp-j-independent manner, Th2 cell differentiation is Rbp-j
dependent (Amsen et al., 2004). It is therefore not surprising
that Il4 and Gata3 were identified as two direct Notch target
genes. The importance of the Rbp-j containing hypersensitive
site 5 (HS5) within a 30 enhancer of the Il4 gene was clearly
demonstrated (Amsen et al., 2004). In CD4+ T cells, Notch1
and Rbp-j could be immunoprecipitated onto the HS5 site of
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that Notch-mediated activation of HS5 within the 30 enhancer is
indeed important for IL-4 expression (Amsen et al., 2004; Tanaka
et al., 2006). These findings suggest that IL-4 is downstream of
Notch signaling, which may explain why Th2 cells could be
generated from Rbp-j-deficient or N1N2-deficient CD4+ T cells
in vitro by adding exogenous IL-4 (Amsen et al., 2007; Tu
et al., 2005). Efficient Th2 cell immune responses are usually
induced after IL-4R signaling, which leads to STAT6 activation
and subsequent increased transcription of Gata3, which is an
important transcription factor for Th2 cell polarization (Ouyang
et al., 2000). Two recent reports showed elegantly that Notch
could directly regulate expression of the Gata3 gene. Notch-
Rbp-j transcription complexes were found to bind to the most
upstream Gata3 promoter and thereby regulate its expression
(Figure 3; Amsen et al., 2007; Fang et al., 2007). Taken together,
these data provide two molecular mechanisms by which Notch-
Rbp-j signaling can promote Th2 cell differentiation. The first
consists in driving transcription of the Gata3 gene. Increased
GATA3 protein engages in a positive feedback loop and then
drives its own expression (Fang et al., 2007). Moreover, GATA3
may help to render the Il4 enhancer accessible to Notch, which
then results in increased Il4 gene expression and protein levels.
IL-4 can then bind to the IL-4R receptor and thereby further drive
Th2 cell polarization.
Notch in Th17 and Regulatory T Cells
In addition to the well-described Th1 and Th2 cell subsets, Th17
cells were recently identified and classified as a proinflammatory
subset distinct from Th1 cells (Korn et al., 2009). Dll4-expressing
DCs, when activated with Toll-like receptor (TLR) ligands or
Mycobacterium antigens, can promote the generation of Th17
cells through activation of the Th17 cell-specific transcription
factor RORgt (Ito et al., 2009; Mukherjee et al., 2009). In EAE,
pathogenic Th1 and Th17 cells develop in the central nervous
system, causing autoimmunity. GSI-mediated inhibition of Notch
signaling in this disease model resulted in reduced Th1 and Th17
cytokines (Jurynczyk et al., 2008; Minter et al., 2005). In addition,
specific antibodies against Dll1, which attenuated EAE, have the
opposite effects to antibodies against Jagged1 which exacer-
bated EAE (Elyaman et al., 2007). These results suggest that
Dll ligands on DCs seem to be involved in the promotion of path-
ogenic Th1 and Th17 cells, whereas Jagged ligands might
suppress autoimmunity.
Suppression of autoimmunity could also at least in part be
regulated by the influence of Notch signaling on regulatory T
(Treg) cells. Treg cells have an important role in negatively regu-
lating hyperactive T cells that are induced during strong immune
responses in peripheral tissues. Several reports show that the
presence of Notch ligands (mostly of the Jagged family) can
enhance Treg cell differentiation and function in vitro (Vigouroux
et al., 2003). For example, exposure of Treg cells to Jagged2-ex-
pressing hematopoietic progenitor cells resulted in Treg cell
proliferation and prevented the development of diabetes in an
experimental autoimmune disease model in mice (Kared et al.,
2006). Similar effects have been observed in mice overexpress-
ing N3-ICD (Anastasi et al., 2003; Campese et al., 2009). It is
unlikely that Notch signaling in vivo is required for the develop-
ment of Treg cells because none of the genetic Notch loss-of-function mutant mice reported the lack of Treg cells. Neverthe-
less, a recent report suggests that Notch signaling might coop-
erate with TGF-b signaling components (P-Smad3) to activate
FoxP3 expression (Samon et al., 2008). FoxP3 is an essential
transcription factor regulating Treg cell development and func-
tion. GSI-mediated inhibition of Notch signaling inhibited
TGF-b-induced Foxp3 expression as well as the suppressive
activity of Treg cells in vitro. In vivo administration of GSI also re-
sulted in reduced Foxp3 transcription. Moreover, these mice
developed symptoms of an autoimmune hepatitis, a disease
that was previously shown to result from deregulated TGF-b
signaling and Treg cells (Samon et al., 2008). Collectively, these
results indicate that Notch signaling facilitates the action of
TGF-b to sustain Foxp3 expression in Treg cells in order to main-
tain their immune-suppressive function.
Thus, Notch signaling has been linked to many aspects of
peripheral immune responses. For many of these functions,
Notch is not absolutely required. However, Notch signaling
appears to be critical in fine-tuning immune responses. There
is clearly more work needed to understand the full spectrum of
Notch functions in the periphery.
Notch in T Cell Leukemia
Jeff Sklar and colleagues identified the first human homolog of
the Drosophila Notch gene in the late 1980s (Reynolds et al.,
1987) and beginning of the 1990s (Ellisen et al., 1991) by cloning
and sequencing of a chromosomal translocation within a small
number of T cell lymphoblastic leukemia patient samples. In
this original study, 4 out of 40 screened T cell leukemia patient
samples carried a t(7;9)(q34;q34.3) chromosomal translocation,
which juxtaposes the C-terminal region of EGF repeat 34 of the
humanNOTCH1 gene to the TCR-b enhancer. This translocation
results in the expression of an N-terminal truncated, dominant
active, and ligand-independent human NOTCH1 receptor, which
was named TAN1 for translocation-associated Notch homolog
(Ellisen et al., 1991). The proof that TAN1 is indeed causative
for disease development was shown by murine BM reconstitu-
tion experiments. Mice transplanted with BM progenitors ex-
pressing TAN1 developed T cell neoplasms as early as 2 weeks
after BM transplantation (Pear et al., 1996). Other truncated
Notch isoforms, including Notch2 and Notch3, were subse-
quently shown to induce T cell leukemias when expressed in
BM progenitors or immature thymocytes (Bellavia et al., 2000;
Rohn et al., 1996). Although the association of Notch and T cell
leukemia has been widely demonstrated in mouse models, the
rare frequency (<1%) of the t(7;9) translocation in human T cell
acute lymphoblastic leukemia (T-ALL) patients questioned the
clinical importance of these findings. This changed dramatically
when Aster and colleagues analyzed 96 pediatric primary T-ALL
tumors and thereby found that 55% of the samples had at least
one mutation in the HD or the PEST domain within the NOTCH1
gene, with approximately 20% of tumors having a mutation in
both domains (Weng et al., 2004). Whereas mutations within
the HD domain render Notch1 susceptible to ligand-indepen-
dent S2 cleavage (Malecki et al., 2006), mutations and/or dele-
tions within the PEST domain stabilize the intracellular Notch1
protein (Chiang et al., 2006), because essential recognition
sequences for ubiquitin ligases that ensure a rapid turnover of
the protein get lost. Fbw7 (F-box and WD repeat domainImmunity 32, January 29, 2010 ª2010 Elsevier Inc. 21
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latter context. Fbw7 has multiple targets including c-Myc and cy-
clin E, but it also physically binds to the C terminus of NICD and
targets it for proteosomal degradation (O’Neil et al., 2007;
Thompson et al., 2007). More importantly, the loss-of-function
Fbw7 mutation was indentified in T-ALL cell lines as well as in
a substantial number (20%) of T-ALL patients. Most of the
Fbw7 mutations were identified in patients undergoing disease
relapse, suggesting that these mutations conferred a selective
advantage to tumor cells in order to render them resistant to
the treatment. A causative role for Fbw7 in mouse T-ALL was
confirmed by using conditional gene targeted mice for Fbw7.
These mice exhibited increased Notch protein expression in
thymocytes and developed T cell leukemia over time (Onoyama
et al., 2007). These results suggest that the Fbw7-mediated
regulation of protein stability of Notch is important during
T-ALL development.
Although it is well documented that expression of NICD in BM
progenitors causes a rapid induction of T-ALL, the impact of the
different NOTCH1 mutations for disease development was less
clear and has only recently been addressed. Pear, Aster, and
colleagues tested different human gain-of-function NOTCH1
alleles for their ability to drive ectopic T cell development and
to induce leukemia when expressed in murine BM progenitors.
NOTCH1 mutant alleles that are more commonly found in
T-ALL patients and induce a relatively weak Notch signaling
activity (read out via transcriptional reporter assays) were able
to induce ectopic T cell development but failed to initiate T cell
leukemia. Only uncommon gain-of-function mutations, which
correlated with strong downstream signaling, were able to drive
both ectopic T cell development and T cell leukemia. These
results question the importance of the more frequently observed
NOTCH1 mutations for the development of T cell leukemia.
However, the weak gain-of-function NOTCH1 alleles acceler-
ated the onset of leukemia when tested in combination with
a constitutively active K-Ras oncogene and importantly gave
rise to tumors that were sensitive to inhibition of Notch signaling
(Chiang et al., 2008). These data show that the induction of T cell
leukemia is dependent on the signaling strength of NOTCH1 and
that the signaling strength of the more commonNOTCH1mutant
alleles are insufficient to induce T-ALL on their own. Thus,
NOTCH1 mutations appear to be additional events that can
cooperate with oncogenic hits and thereby influence tumor
development and onset. Importantly, these tumors seem to
remain ‘‘addicted’’ to NOTCH signaling (Chiang et al., 2008),
which justifies further exploration of Notch inhibitors for treating
T cell leukemia.
One important question that gained a lot of attention in the
past years is the identification of target genes and signaling path-
ways that are regulated by or cooperate with mutant NOTCH1
alleles in T-ALL. Gene expression arrays performed by several
laboratories identified c-Myc as an important Notch target
gene. c-Myc is rapidly downregulated in murine and human
T-ALL cell lines upon GSI-mediated inhibition of Notch. c-Myc
expression was also directly correlated to NICD expression
and ChIP analysis revealed c-Myc to be a direct target of
NOTCH1 (Weng et al., 2006). Ferrando and colleagues extended
these findings and came to similar conclusions by performing
‘‘ChIP on ChIP’’ analysis and thereby showed that c-Myc and22 Immunity 32, January 29, 2010 ª2010 Elsevier Inc.NICD share common targets, regulating cell growth, metabo-
lism, and proliferation. They proposed a feed-forward loop
through which NOTCH1 and c-Myc reinforce the expression of
genes required for growth of leukemic cells (Figure 4; Palomero
et al., 2006).
Aberrant Notch signaling is directly linked to the regulation of
cell cycle proteins. Protein amounts of the cell cycle-dependent
kinase inhibitor p27Kip1 increased upon Notch inhibition. Notch
signaling induces the transcriptional expression of the F-box
protein Skp2, which is part of the E3-ligase complex that
degrades p27Kip1 and p21Cip1, leading to enhanced G1-S transi-
tion (Sarmento et al., 2005). In mouse models, p27Kip1 deficiency
itself was shown to contribute to T-ALL development (Kang-
Decker et al., 2004). Another cell cycle protein involved in
Notch-induced T-ALL is cyclin D3. Mice lacking cyclin D3
show greatly reduced susceptibility to Notch-induced leukemo-
genesis, suggesting that cyclin D3 might be an essential cell
cycle protein through which Notch mediates its oncogenic
effects (Sicinska et al., 2003). With a tetracycline-inducible
mouse model for Notch-induced T cell leukemia, Notch was
shown to suppress p53 through repression of the ARF-mdm2-
p53 surveillance network (Beverly et al., 2005). Attenuation of
Notch signaling led to increased p53 expression and to tumor
regression by inducing apoptosis (Beverly et al., 2005). Thus,
Notch-mediated suppression of p53 appears to be another
important event for T-ALL development (Figure 4).
Protein microarray screens identified the mTOR pathway as
being positively regulated by Notch in T-ALL cells. Treatment
of T cell leukemia cell lines with GSI induced hypophosphoryla-
tion of multiple signaling proteins within the mTOR pathway,
a phenomenon that could be rescued by expressing NICD.
Expression of a dominant-negative MAML-1 also mimicked the
GSI effects, suggesting that activation of the mTOR pathway
involves transcriptional activation of Notch target genes. How
Notch activates the mTOR pathway is not fully understood. Inter-
estingly, the effects of GSI on mTOR were rescued by expression
of c-Myc and because c-Myc is a direct target gene of Notch, it is
possible that mTOR is activated via c-Myc (Chan et al., 2007). An
alternative possibility, as suggested in flies and in human T-ALL
cell lines, is that the Notch target gene Hes1 can negatively regu-
late the expression of PTEN (Palomero et al., 2007). PTEN is
a tumor suppressor that counteracts the PI3-kinase activity
and thereby negatively regulates the Akt pathway and its down-
stream target mTOR (Figure 4). In this context, loss of PTEN was
suggested to induce resistance to NOTCH1 inhibition in T cell
leukemia (Palomero et al., 2007). This hypothesis was
challenged by showing that primary murine T cell leukemias
remained dependent on Notch signaling despite the loss of
PTEN. Moreover, investigations of 13 primary human T-ALL
samples did not show any correlation between the PTEN status
and resistance to Notch inhibition. However, loss of PTEN-accel-
erated disease onset in a murine T-ALL model suggested that
Notch1 activation and loss of PTEN may collaborate in leukemia
induction (Medyouf et al., 2009).
Another signaling pathway that becomes activated in
response to the expression of NICD or human T-ALL NOTCH1
mutations in hematopoietic progenitors is the NF-kB cascade.
NICD expression could induce the nuclear localization of NF-
kB, which resulted in the expression of multiple NF-kB targets
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Figure 4. Molecules and Signaling Pathways Downstream of Notch
Mediated T-ALL Induction
Arrows indicate positive and bars negative regulatory interactions contributing
to the development and/or maintenance of T-ALL. Growth-promoting mole-
cules or pathways are highlighted in blue, whereas growth-inhibitory mole-
cules are shown in purple. Details of the molecules involved are described in
the text. NFAT, nuclear factor-activated T cells; PTEN, phosphatase and tensin
homolog; PI3K, phosphoinositol 3-kinase; mTOR, mammalian target of rapa-
mycin.
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Review(including Bcl-2A1, NF-kB2, and ICAM1). Importantly, attenua-
tion of NF-kB signaling resulted in the suppression of T cell
leukemia both in vitro and in vivo (Vilimas et al., 2007). Finally,
the NFAT cascade was also shown to be activated in response
to aberrant Notch signaling. Notch activates calcineurin, which
is a calcium-activated phosphatase that is important for the acti-
vation and translocation of NFAT factors from the cytoplasm to
the nucleus. Calcineurin inhibitors such as Cyclosporin A (CsA)
or FK506 induced cell death of T-ALL cells and resulted in tumor
regression as well as in substantial prolonged survival of
leukemic mice (Figure 4; Medyouf et al., 2007). In this context,
it is interesting to note that c-myc, NF-kB, and NFAT are all
signaling pathways that also get activated when immature
thymocytes transit through b-selection.
Although the details of how Notch regulates and intersects
with all these different signaling pathways are not fully under-
stood, they highlight important connections and open possibili-
ties to treat T-ALL from different angles. To date, the most
frequently used strategy to block Notch signaling that is also
currently explored in clinical trials is to use small molecule inhib-
itors of the g-secretase complex (Seiffert et al., 2000). These
molecules block the S3 cleavage and thereby inhibit the libera-
tion of NICD (Seiffert et al., 2000). However, g-secretase inhibi-
tors are not NOTCH specific nor are they selective for individualNotch receptors; they block signaling of all receptors. Adminis-
tration of g-secretase inhibitors to mice or T-ALL patients results
in unwanted side effects including dose-dependent gastrointes-
tinal toxicity (Milano et al., 2004). Alternative strategies such as
designing blocking antibodies for specific Notch receptors
and/or ligands are currently being developed by several groups
and pharmaceutical companies. A strategy for inhibiting Notch
signaling was successfully explored by Bradner and colleagues,
who aimed at inhibiting the NOTCH transcription complex. The
design of the new inhibitors is based on the X-ray structure of
the CSL-NICD-dnMAML complex (Nam et al., 2006). The
dnMAML protein forms a long a helix that is located in a groove
formed by the CSL-NICD complex. Bradner and colleagues de-
signed and tested small a-helical peptides (hydocarbon-stapled
a-helical peptides) for their ability to mimic this a helix and then
bind to and thereby block the intracellular protein-protein inter-
action. Treatment of leukemic cells with such a peptide resulted
in the suppression of the Notch-activated transcriptome. Most
importantly, the peptide inhibited the proliferation of leukemic
cells in vitro as well as in a NOTCH1-driven T-ALL mouse model
without causing gut toxicity (Moellering et al., 2009). Whether
these a-helical peptides are specific inhibitors of the NOTCH1
transcription complex remains to be investigated. Nevertheless,
this is a very encouraging study showing that transcription factor
complexes can indeed be targeted (Moellering et al., 2009).
Conclusions
Over the last decade, Notch signaling was shown to regulate
multiple cell fate decision and differentiation processes during
development and function within the hematopoietic system.
Most, if not all, of these functions seem to be mediated through
canonical (Rbp-j-mediated) Notch signaling. Notch is essential
for the development of definitive hematopoiesis during embryo-
genesis, whereas under physiological conditions it is dispens-
able for the maintenance or homeostasis of adult HSCs. Further-
more, it is absolutely necessary for T cell lineage commitment
and early stages of thymocyte as well as for MZB cell develop-
ment. All these developmental aspects of Notch function are
mediated by nonredundant Notch receptor ligand pairs (Jag-
ged1:Notch1 for embryonic HSCs; Dll4:Notch1 for thymocyte
development, and Dll1:Notch2 for MZB cell development). In
more recent years, investigators found increasing evidence
that Notch also plays important roles during T cell-mediated
immune responses, in particular for the regulation of T helper
cell differentiation. Genetic loss-of-function experiments point
to an essential role of Notch signaling in Th2 cell differentiation.
Nevertheless, Notch seems also to influence Th1 cell differenti-
ation. Th1 and Th2 cell differentiation may depend on the ligand
used to activate Notch. The question of ligand receptor speci-
ficity is currently unclear and will need to be answered in the
future. Moreover, it is not known how Jagged- and Dll-express-
ing APCs differ in their ability to induce Notch signaling. Is
this a question of signaling strength and how does this translate
into differential target gene expression followed by Th cell
differentiation?
The disease outcome of several patient-relevant experimental
murine autoimmune models can be influenced by interfering with
Notch signaling, suggesting that inhibitors or activators of Notch
might be used to treat inflammatory and/or autoimmuneImmunity 32, January 29, 2010 ª2010 Elsevier Inc. 23
Immunity
Reviewdiseases. In this context, it is important to note that many func-
tions of Notch are conserved between mice and men. Neverthe-
less, the effects of interfering with Notch signaling in human
systems remain to be systematically investigated.
Although the oncogenic properties of Notch signaling for
T-ALL were discovered approximately 20 years ago, research
in this field gained increasing interest only after the finding that
gain-of-function NOTCH1 mutations are the most frequent
genetic alterations found in T-ALL. The predominant role of
Notch signaling in T-ALL cells is to drive a gene expression
program maintaining growth, high metabolism, and survival.
Thus, the Notch pathway became an attractive therapeutic
target and multiple tools (e.g., g-secretase inhibitors, neutral-
izing antibodies against Dll4 or NOTCH1) that interfere with
Notch signaling are currently being developed and tested in
various murine cancer models or even in clinical trials. In the
future, the same tools might also be exploited to treat immuno-
logical disorders.ACKNOWLEDGMENTS
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